|
Forward-looking intelligence allows you time to act. View this video on our restructuring content to see how you can benefit from our expertise.
| ||
NOT A SUBSCRIBER?Bristol's dance cardPosted on November 6, 2009 5:30 PM
At Bristol-Myers Squibb Co., the race is on to replace the pharmaceutical giant's biggest cash cow, the $6 billion-a-year moneymaker Plavix, a blood clot inhibitor whose patents expire in the first half of 2012.
James Cornelius, the drugmaker's chief executive, told analysts last month that Bristol has $1.3 billion in cash on hand and could soon have a further $1.75 billion as the result of a refinancing by Mead Johnson, in which Bristol still owns a majority stake. This is a free content preview. Subscribers enjoy access to all stories in full as well as second-to-none market intelligence. Dig deeper, with Pipeline.
Most searched keywords
|
|
EXISTING USERS Missing a product? |
Michael Crosby mcrosby@thedeal.com 212.313.9325 |
Martha Brown mbrown@thedeal.com 212.313.9218 |